Menu
Professional & Student Poster Presentations
Professional
- PP01-01: Machine-Learning-Based Identification of Risk Factors for Immune-Related Adverse Events Using Clinical Trial Data
- PP01-03: A Socio-Technical Approach to Improve Patient Safety Evaluation and Action Across the Healthcare Ecosystem
- PP01-05: Converting EU-RMPs to the GVP Module V Rev 2 Format: Impactful Results and Lessons Learned
- PP01-07: Conversational Interfaces for Data Mining in Pharmacovigilance
- PP01-09: Depression Among People Living With HIV/AIDS: Real-World Application of Deep Neural Networks
- PP01-10: A Retrospective Analysis of Baseline Liver Function Parameters in Subjects with Mild, Moderate, or Severe Hepatic Impairment
- PP01-12: Sound the Alarm: Identifying Drug Characteristics Leading to FDA Label Changes
- PP01-15: Effective Educational and Training Methods Applicable to Risk Evaluation and Mitigation Strategies (REMS): A Scoping Review
- PP01-16: European Physician Perspectives on Biosimilars
- PP01-17: Establishing a Strategic Intelligence Capability within Pharmacovigilance
- PP01-18: Effectively Managing Oversight of Responsibilities in Safety Data Exchange Agreements to Ensure Regulatory Compliance
- PP01-19: Applying User Experience Research to Understand Medical Evaluation of Adverse Events
- PP02-22: A Bayesian Approach to Design and Evaluation of Multiregional Clinical Trial
- PP02-23: Placebo Response Reduction Training Increases Assay Sensitivity in Clinical Trials on Migraine Treatment
- PP02-24: Electronic Trial Master File (eTMF) Automation using Intelligent OCR and RPA
- PP02-25: Socio-Ecological Elements Involved in Racial and Ethnic Minority Recruitment Practices for Industry-Sponsored Clinical Trials
- PP02-26: Diversity in Phase I/II/III Lung Cancer Clinical Trials: A Systematic Literature Review of Patient Racial Demographics
- PP02-27: Clinical Trial Enrollment and Retention with eConsent vs. Paper Consent
- PP03-34: Monitor What Matters: Validation of a Key Risk Indicator Selection Method That Predicts Study Outcome
- PP03-36: Classification of Electronic Medical Record Laboratory Data using Machine Learning Techniques
- PP04-38: Assessment of Peer Review Comments and Publication Metrics From Comparative Effectiveness Research (CER) Studies
- PP04-39: Evaluation of Pharmaceutical Industry Medical Engagement Content for Healthcare Professionals, Patients, and Caregivers
- PP05-40: Patient Experience Data in the Treatment Resistant Depression Esketamine NDA: Patient-Reported Outcomes and Patient Preferences
- PP05-41: How to Establish a Patient Publication Steering Committee for a Global Biopharmaceutical Company: A Feasibility Case Study
- PP05-42: Implementing Digital Technologies in Neurology and Respiratory Clinical Trials: Lessons Learned
- PP05-43: Understanding and Addressing the Holistic Rare Disease Patient Experience Through Community Advisor Program
- PP05-45: What Pharmaceutical Company Leaders Say and What Patient Leaders Think: Quantitative and Qualitative Analyses
- PP06-49: How to Prioritize Indications in Early Clinical Development Using a Decision Framework to Assess the Overall Attractiveness
- PP06-50: Development of an Intelligent Visulization Platform to Drive Enhanced Decision-Making at The First-In-Human Stage
- PP07-53: An Emergent Behavioral Capability Model to Enable Transformation
- PP07-54: Global Pharmacovigilance Strategic Management and Oversight: Study of A Partnership Model
- PP08-56: The Quality and Compliance Benefits to eConsent
- PP09-59: U.S. FDA Adverse Event Reporting System (FAERS) Reporting Post Marketing Trends for Product Name Confusion, 2009 to 2019
- PP09-61: CPP Requirements for the Registration of Medicines in the Region of the Americas
- PP09-62: Otsuka’s Journey Leveraging the Power of Digital/Social Media Platforms to Compliantly Meet Innovative Business Objectives
- PP09-63: Registry-Based Randomized Clinical Trial (R-RCT) – The Future of RWE Registration Trial
- PP09-64: Key Themes from Comments Received to the Framework of the FDA’s Real-World Evidence Program
- PP09-65: US Accelerated Approval (AA) Withdrawals
- PP09-66: Otsuka eWriter: An Automated Authoring Tool for Patient Narratives
- PP09-67: Opportunities for Regional Convergence - Regulation of Advanced Therapy Medicinal Products in Asia Pacific
- PP09-68: A Large Company's Submission Planner: A Tool to Plan, Resource, and Process Publishing Projects via Automated Workflows/Data Analytics
- PP09-69: Analysis of Expedited Approval Pathways for Approved New Molecular Entities in Oncology
- PP10-75: Application of ICH S9 and Haber’s Law for Impurities Specifications in a High Dose Early Development Oncology Program
- PP10-76: Generic Ophthalmic Products: Regulatory Considerations for Product Quality
- PP10-77: Risk-Based Quality Assessment of Generic Narrow Therapeutic Index Drugs
- PP10-78: Risk-based Assessment of Generic Drug Storage Conditions That Differ from Reference Listed Drugs (RLD)
- PP11-80: Statistical Concerns For Cut Point Determination in Immunogenicity Studies
- PP11-81: Utilizing a Bayesian Hierarchical Model to Design Quality Into a Clinical Trial and Allow Compliance with ICH E6 R2 Quality T
- PP11-82: Going Upstream in Machine Learning; The Importance of Feature Engineering With Examples From a Surgical ICU
- PP11-83: Exploration of Statistical Methods for Seizure Frequency in Epilepsy Trials
- PP12-88: Does Current Practice Reflect the Value of Rapid Diagnostics? US Patterns in the Time to Completion of Microbiology Results
- PP12-89: Reimbursement of Orphan Drugs in EU-5 between 2010-2019: A Landscape Assessment
- PP12-90: Payer Survey Reveals Confusion Around the Definition and Utility of Real-World Evidence in Rare Disease Coverage Decisions
Student
- SP01-20: A Latest Patent-Based Snapshot of Research and Development of Chimeric Antigen Receptor (CAR)-T cell Therapy
- SP01-21: Assessment of Knowledge of Warfarin therapy and Anticoagulation Control in Patients at a Tertiary Care Public Hospital
- SP02-30: Utilization of Wearables and Trends in mHealth in Current Clinical Research of Neurologic Conditions
- SP02-31: Evaluation of Scientific Evidence and Implementation Challenges to Precision Medicine for Acute Myeloid Leukemia Patients
- SP02-32: Examination of FDA Pediatric Regulations: Inclusion of Pediatric Participants in Clinical Trials
- SP02-33: Augmenting Randomized Control Trials with Real World Data to Improve Clinical Decision Making and Outcomes Within Oncology
- SP05-46: Plain Language Clinical Trial Result Summaries: Are Participants Getting It?
- SP05-47: Path to Corporate Leadership: Profiles of Chief Executive Officers of the Top 20 Pharmaceutical Companies
- SP05-48: Association between Cognitive Impairment and Suicidal Ideation in Patients with Major Depressive Disorder: A Prospective Study
- SP06-51: The Pharmacokinetics and Dose Strategy of Monoclonal Antibodies in Pediatrics
- SP06-52: Analgesic & Neuroprotective Effect of S-adenosyl L-Methionine (SAM) on Nitro-glycerine (NTG) induced Migraine in Albino Mice
- SP08-58: Targeting ß-catenin Activity Enhances the Therapeutic Efficacy of the EGFR TKI, osimertinib in EGFR Mutant Non-Small Cell Lung
- SP09-71: Improving Pediatric Prescribing: Measuring the Impact of Legislative Initiatives
- SP09-72: The Comparative Analysis of FDA and EMA’s Initiatives to Advance the Practice and Use of Real-World Evidence
- SP09-73: Effect of the Pennsylvania Prescription Drug Monitoring Program on Opioid Dispensing in a Medicaid Population
- SP09-74: Optimizing Written Information for Prescription Medicines
- SP11-84: Impact of Different Randomization Techniques on the Statistical Efficiency in Clinical Trials
- SP11-85: Medical Insurance Participation and the Novel Coronavirus Epidemic in Hubei, China: An Empirical Study based on CLDS
- SP12-91: Association of Asthma COPD Overlap to Cost-Related Medication Nonadherence among Older Adults in the United States
- SP12-92: Gender Disparities in Receipt of Anti-dementia Medications among Medicare Beneficiaries in the U.S.
- SP13-95: Relationship Between Professional Identity and Social Support Among Pharmaceutical Staffs in Northwestern China
- SP13-96: Dispensing Mifepristone for First-Trimester Medical Abortion in Canada: Survey Results of Pharmacists Perspectives